Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infectionsShow others and affiliations
2017 (English)In: Sexually Transmitted Infections, ISSN 1368-4973, E-ISSN 1472-3263, Vol. 93, no Suppl. 4, p. S16-S21Article, review/survey (Refereed) Published
Abstract [en]
Background: In 2012, there was an estimated 78 million new cases of gonorrhoea globally. Untreated infection may lead to reproductive and neonatal morbidity and facilitate HIV transmission. Diagnosis and treatment are a priority for control and prevention, yet use of point-of-care tests (POCTs) for Neisseria gonorrhoeae (NG) is limited.
Objectives: To review the performance and operational characteristics of NG POCTs for diagnosis of urogenital gonorrhoea.
Methods: We compiled and synthesised findings from two separate systematic reviews which included evaluations published until August 2015.
Results: Six tests were included: five were immunochromatographic tests (ICTs) or optical immunoassay (OIAs) based on antigen detection; with 5-7 steps and results in 25-40 min, and one (GeneXpert CT/NG) was a 'near-patient test' based on nucleic acid amplification technique (NAAT); with three steps, electricity required, and results in 90 min. When compared with laboratory-based NAATs as the reference tests, sensitivities of ICT and OIA-based POCTs ranged from 12.5% to 70% when cervical/vaginal swabs were tested. Specificities ranged from 89% to 99.8%. The near-patient NAAT had sensitivities of >95% and specificities of >99.8% consistently across all specimen types (urine, cervical and vaginal swabs).
Conclusions: Based on a limited number of evaluations, antigen detection POCTs for NG lacked sufficient sensitivity to be used for screening. A near-patient NAAT has acceptable performance, only involved a few steps, but needs electricity, a temperature-controlled environment and has a 90 min run time. To achieve wider scale up of NG POCTs, we need strong evidence of cost-effectiveness, which should inform guidelines and ultimately increase test development, demand and reduce costs.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2017. Vol. 93, no Suppl. 4, p. S16-S21
National Category
Infectious Medicine Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:oru:diva-65036DOI: 10.1136/sextrans-2017-053192ISI: 000424009900003PubMedID: 29223959Scopus ID: 2-s2.0-85043709631OAI: oai:DiVA.org:oru-65036DiVA, id: diva2:1183274
2018-02-162018-02-162023-12-08Bibliographically approved